Evidence map›Paper›PMID 36388462›Full record

ReviewMaterials today. Bio2022

Optical diagnostic imaging and therapy for thyroid cancer.

Chengying Shao, Zhenfang Li, Chengchi Zhang, Wanchen Zhang, Ru He, Jiajie Xu, Yu Cai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Pre-clinical study of IR808 dye for cervical cancer in vitro and in vivo imaging.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chengying ShaoOtolaryngology& Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China.
Zhenfang LiSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou 310012, China.
Chengchi ZhangZhejiang University of Technology, Hangzhou, 310023, China.
Wanchen ZhangOtolaryngology& Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China.
Ru HeSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou 310012, China.
Jiajie XuOtolaryngology& Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China.
Yu CaiClinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer, as one of the most common endocrine cancers, has seen a surge in incidence in recent years. This is most likely due to the lack of specificity and accuracy of its traditional diagnostic modalities, leading to the overdiagnosis of thyroid nodules. Although there are several treatment options available, they are limited to surgery and

Indexed as

131I-BSA@CuS, 131I-labeled BSA-modified CuS nanoparticles5-ALA, 5-Aminolevulinic acidASIR, age-standardized rates of cancer incidenceATC, anaplastic thyroid carcinomaAu@MSNs, photo-triggered Gold nanodots capped mesoporous silica nanoparticlesAuNCs@BSA-I, innovative iodinated gold nanoclustersBRAF, V-Raf murine sarcoma viral oncogene homolog BCBDCA, CarboplatinCDFI, color doppler flow imaging ultrasoundCLND, central compartmentalized node dissectionCPDA-131I NPs, the 131I-radiolabeled cerebroid polydopamine nano-particlesCT, Computed TomographyDOT, Diffuse Optical TomographyDTC, differentiated thyroid cancerECDT, enhanced chemodynamical therapyEGF, epidermal growth factorEGFR, epidermal growth factor receptorESMO, European Society of Medical OncologyFDA, U.S. Food and Drug AdministrationFI, fluorescence imagingFNAB, fine-needle aspiration biopsyFNAs, fine needle aspirationsFTC, follicular thyroid carcinomaGC, germinal centerHAOA, Hyaluronic Acid and Oleic AcidHYP, hypericinICG, indocyanine greenIJV, internal jugular veinIR825@B-PPNs, Polymeric NPs with bevacizumab and IR825 conjugated on the surfaceL-A PTA, laparoscopic photothermal ablationMDR, multidrug resistancemETE, microscopic extrathyroidal extensionMTC, medullary thyroid carcinomaMultimodal therapyNIR-FI, near-infrared fluorescence imagingNIRF, near-infrared fluorescenceNIR, near-infraredNIR-PIT, near-infrared photoimmunotherapyNMRI, Nuclear Magnetic Resonance ImagingOCT, Optical Coherence TomographyOI, optical imagingOptical imagingOptical imaging-guided surgeryOS, overall survivalPAI, Photoacoustic ImagingPd-MOF, porphyrin–palladium metal–organic frameworkPDT, photodynamic therapyPET, Positron Emission TomographyPGs, parathyroid glandsPhototherapyPLP, porphyrin-HDL nanoparticlePTA, photothermal reagentsPTC, papillary thyroid carcinomaPTT, photothermal therapyRIT, radioactive iodine therapyROS, reactive oxygen speciesSEC, SelenocysteineSiRNA, interfering RNASV, subclavian veinTC, thyroid cancerTD, Thoracic DuctTF, tissue factorThyroid cancer

Identifiers

PMID36388462
PMCPMC9640994

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.